551 related articles for article (PubMed ID: 32349307)
1. Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole-Indole Conjugates as Anticancer CDK Inhibitors.
Al-Warhi T; El Kerdawy AM; Aljaeed N; Ismael OE; Ayyad RR; Eldehna WM; Abdel-Aziz HA; Al-Ansary GH
Molecules; 2020 Apr; 25(9):. PubMed ID: 32349307
[TBL] [Abstract][Full Text] [Related]
2. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and
Eldehna WM; Al-Rashood ST; Al-Warhi T; Eskandrani RO; Alharbi A; El Kerdawy AM
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):270-285. PubMed ID: 33327806
[TBL] [Abstract][Full Text] [Related]
3. Design and Synthesis of New
Farghaly TA; Pashameah RA; Bayazeed A; Al-Soliemy AM; Alsaedi AMR; Harras MF
Med Chem; 2024; 20(1):63-77. PubMed ID: 37723960
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.
Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872
[TBL] [Abstract][Full Text] [Related]
6. Targeting tyrosine kinase: Development of acridone - pyrrole - oxindole hybrids against human breast cancer.
Kaur M; Singh P
Bioorg Med Chem Lett; 2019 Jan; 29(1):32-35. PubMed ID: 30446310
[TBL] [Abstract][Full Text] [Related]
7. Marine-Inspired Bis-indoles Possessing Antiproliferative Activity against Breast Cancer; Design, Synthesis, and Biological Evaluation.
Eldehna WM; Hassan GS; Al-Rashood ST; Alkahtani HM; A Almehizia A; Al-Ansary GH
Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32252280
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of novel oxindole-based RTK inhibitors as anti-cancer agents.
Chen G; Weng Q; Fu L; Wang Z; Yu P; Liu Z; Li X; Zhang H; Liang G
Bioorg Med Chem; 2014 Dec; 22(24):6953-60. PubMed ID: 25456085
[TBL] [Abstract][Full Text] [Related]
10. Selective CDK4/6 inhibition of novel 1,2,3-triazole tethered acridinedione derivatives induces G1/S cell cycle transition arrest via Rb phosphorylation blockade in breast cancer models.
Praveenkumar E; Gurrapu N; Kolluri PK; Shivaraj ; Subhashini NJP; Dokala A
Bioorg Chem; 2021 Nov; 116():105377. PubMed ID: 34670329
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, in vitro anticancer activity and in silico studies of certain pyrazole-based derivatives as potential inhibitors of cyclin dependent kinases (CDKs).
Mohammed EZ; Mahmoud WR; George RF; Hassan GS; Omar FA; Georgey HH
Bioorg Chem; 2021 Nov; 116():105347. PubMed ID: 34555628
[TBL] [Abstract][Full Text] [Related]
12. New antiproliferative 3-substituted oxindoles inhibiting EGFR/VEGFR-2 and tubulin polymerization.
Ezelarab HAA; Ali TFS; Abbas SH; Sayed AM; Beshr EAM; Hassan HA
Mol Divers; 2024 Apr; 28(2):563-580. PubMed ID: 36790582
[TBL] [Abstract][Full Text] [Related]
13. Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides.
Eldehna WM; El Kerdawy AM; Al-Ansary GH; Al-Rashood ST; Ali MM; Mahmoud AE
Eur J Med Chem; 2019 Feb; 163():37-53. PubMed ID: 30503942
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: Design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents.
Eldehna WM; Abo-Ashour MF; Nocentini A; El-Haggar RS; Bua S; Bonardi A; Al-Rashood ST; Hassan GS; Gratteri P; Abdel-Aziz HA; Supuran CT
Eur J Med Chem; 2019 Jan; 162():147-160. PubMed ID: 30445264
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and SARs study of novel spiro-oxindoles as potent antiproliferative agents with CDK-2 inhibitory activities.
Al-Jassas RM; Islam MS; Al-Majid AM; Nafie MS; Haukka M; Rahman AFMM; Alayyaf AMA; Barakat A
Arch Pharm (Weinheim); 2023 Aug; 356(8):e2300185. PubMed ID: 37253118
[TBL] [Abstract][Full Text] [Related]
16. Development of isatin-thiazolo[3,2-a]benzimidazole hybrids as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological and molecular dynamics investigations.
Eldehna WM; El Hassab MA; Abo-Ashour MF; Al-Warhi T; Elaasser MM; Safwat NA; Suliman H; Ahmed MF; Al-Rashood ST; Abdel-Aziz HA; El-Haggar R
Bioorg Chem; 2021 May; 110():104748. PubMed ID: 33684714
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers.
El-Sharief AMS; Ammar YA; Belal A; El-Sharief MAMS; Mohamed YA; Mehany ABM; Elhag Ali GAM; Ragab A
Bioorg Chem; 2019 Apr; 85():399-412. PubMed ID: 30665034
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of novel indole-pyrimidine hybrids bearing morpholine and thiomorpholine moieties.
Diao PC; Li Q; Hu MJ; Ma YF; You WW; Hong KH; Zhao PL
Eur J Med Chem; 2017 Jul; 134():110-118. PubMed ID: 28410492
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
Shaheen MA; El-Emam AA; El-Gohary NS
Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and molecular docking studies of thymol based 1,2,3-triazole hybrids as thymidylate synthase inhibitors and apoptosis inducers against breast cancer cells.
Alam MM; Malebari AM; Syed N; Neamatallah T; Almalki ASA; Elhenawy AA; Obaid RJ; Alsharif MA
Bioorg Med Chem; 2021 May; 38():116136. PubMed ID: 33894490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
